Taysha gene therapies announces presentations at the upcoming 29th annual meeting of the european society of gene & cell therapy (esgct)

Dallas, oct. 06, 2022 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced two poster presentations at the upcoming 29th annual meeting of the european society of gene & cell therapy (esgct) in cooperation with the british society of gene & cell therapy (bsgct) taking place in edinburgh, scotland from october 11-14, 2022.     poster presentation details
TSHA Ratings Summary
TSHA Quant Ranking